82
Participants
Start Date
February 20, 2015
Primary Completion Date
February 9, 2017
Study Completion Date
July 21, 2021
Lenalidomide
Dexamethasone
Elotuzumab (BMS-901608)
Local Institution, Bunkyo-ku
Local Institution, Koto-ku
Local Institution, Shibuya-ku
Local Institution, Shinjuku-Ku
Local Institution, Shinjuku-ku
Local Institution, Tachikawa-shi
Local Institution, Chiba
Local Institution, Kamogawa-shi
Local Institution, Kasama-shi
Local Institution, Utsunomiya
Local Institution, Kawagoe-shi
Local Institution, Maebashi
Local Institution, Shibukawa-shi
Local Institution, Hamamatsu
Local Institution, Nagoya
Local Institution, Nagoya
Local Institution, Osaka
Local Institution, Osaka
Local Institution, Kyoto
Local Institution, Okayama
Local Institution, Fukuyama-shi
Local Institution, Matsuyama
Local Institution, Fukuoka
Local Institution, Kagoshima
Local Institution, Niigata
Local Institution, Sendai
Local Institution, Aomori
Local Institution, Morioka
Lead Sponsor
Collaborators (1)
AbbVie
INDUSTRY
Bristol-Myers Squibb
INDUSTRY